SCRS Global Impact Partner program announced it has gained four new members since April 1.
The Society for Clinical Research Sites' (SCRS) Global Impact Partner (GIP) program at announced it has gained four new members since April 1. These companies are INC Research, inVentiv Health, Novartis and Sanofi, which now brings the total number of companies in the initiative to 25. Global Impact Partners participate on the SCRS Global Impact Board at an executive level and work in tandem with the SCRS Leadership Council. They serve as strategic partners and help set key initiatives for the Society to elevate site performance and enhance site sustainability.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.